• Regeneron Pharmaceuticals average return on tangible equity for 2023 was 18.33, a 39.96% decline from 2022.
• Regeneron Pharmaceuticals average return on tangible equity for 2022 was 30.53, a 36.09% decline from 2021.
• Regeneron Pharmaceuticals average return on tangible equity for 2021 was 47.77, a 70.85% decline from 2020.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.